NK:IO

NK:IO is a biotechnology company developing cancer immunotherapies based on human natural killer cells. Its work focuses on harnessing the innate immune system to create new treatments for haematological and solid tumours. The company’s platform uses discoveries in stem cell biology, small-molecule and peptide-ligand activation to expand and enhance NK cells for therapeutic use. Its programmes include cord-blood-derived NK cell therapies designed to improve tumour-killing capacity and overcome exhaustion, with candidates currently in research and early preclinical development. NK:IO operates in the life sciences, oncology, cell therapy and advanced therapeutics industry.